1. Kao WY, Su CW, Chiou YY, Chiu NC, Liu CA, Fang KC, Huo TI, Huang YH, Chang CC, Hou MC, Lin HC, Wu JC. Hepatocellular carcinoma: Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. Radiology 2017;285:670-680 (SCI, IF: 29.146) (The first two authors [Kao WY and Su CW] have contributed equally to this work)
2. Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12 (Suppl 1):56-67 (SCI, IF: 9.029)
3. Chen PH, Hsieh WY, Su CW*(corresponding author), Hou MC*, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY, Wu JC. Combination of albumin-bilirubin grade and platelet to predict compensated patient with hepatocellular carcinoma who do not require endoscopic screening for esophageal varices. Gastrointest Endosc 2018:88:230-9 (SCI, IF: 10.396)
4. Fang KC, Kao WY, Su CW*(corresponding author), Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC*. The prognosis of single large hepatocellular carcinoma was distinct from the BCLC stage A or B: The role of albumin-bilirubin grade. Liver Cancer 2018;7:335-58 (SCI, IF: 12.430)
5. Kao WY, Su CW*(corresponding author), Tan ECH*, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton pump inhibitors and risk of hepatocellular carcinoma in patients with chronic hepatitis B or C. Hepatology 2019;69:1151-64 (SCI, IF: 17.298)